Fractyl Health (GUTS) Q2 FY26 earnings call: guidance and Q&A

What procedure volume per center is embedded in the profitability assumption for a targeted launch into top 100-200 US centers, and how quickly do physicians ramp up?

Management deferred specific numbers to the upcoming Investor Day but stated that the health economic value proposition for Revita is greater than previously realized, increasing confidence in profitability. Physicians typically become comfortable with the procedure after less than five procedures, leveraging existing skills.

“Well, that's actually a wonderful question that preps for our investor day that's coming in early September, where we can address our view on the commercial opportunity ahead of us. But I'm not going to front run with specific numbers in that regard.”

asked by Michael DiFiore · answered by Harith Rajagopalan

What criteria (prior GLP-1 use, weight loss, BMI, discontinuation) do they expect payers or Medicare to impose for Revita reimbursement?

Management expects payers to closely follow the patient population studied in the pivotal trial, likely requiring at least 15% run-in weight loss and prior GLP-1 therapy. Medicare is particularly concerned about muscle mass loss and frailty in the elderly population on GLP-1s, and the impending discontinuation of many patients from the GLP-1 Bridge program.

“I expect that Medicare will follow the, I expect that payers will be looking very carefully at the patient population that was studied and pre-specified in the pivotal trial. And While I can't speak to what the label might say, I would expect that the payers are going to look very carefully at this, at least 15% run in weight loss and the use of GLP-1 therapy or GLP-1-based therapy rather than terseptide specifically.”

asked by Michael DiFiore · answered by Harith Rajagopalan

What are the expectations for TCET upon approval, any risks with filing timeline (de novo vs. PMA)? And details on the commercial infrastructure build-out for Revita.

Breakthrough devices like Revita are eligible for transitional pass-through payment from CMS if novel and not fitting existing CPT schema, allowing for reimbursement from day one post-launch. The commercial strategy will be a targeted center of excellence model focusing on the top 100-200 endoscopy health systems, leveraging existing relationships and high throughput.

“So with respect to initial payment, there is a mechanism called transitional pass-through through CMS that has a quarterly review cycle and a statutory requirement for payment that is actually quite clear. Breakthrough devices have an exemption through transitional pass-through.”

asked by Jason Gerberry · answered by Harith Rajagopalan

Confirmation of final SAP submission for Revita and any FDA response. Also, details on the patent estate for ablation technologies, especially for weight maintenance.

The final SAP was submitted and locked, with FDA correspondence being minor and non-material. The company has a broad and comprehensive patent estate covering thermal and non-thermal ablation modalities for the duodenum, including for post-GLP-1 weight maintenance, type 2 diabetes, and related conditions, and intends to defend it.

“Yes, final SAP was submitted. I think we mentioned that in our July call. And we are locked and loaded heading into our database lock.”

asked by Unknown Speaker · answered by Harith Rajagopalan

Are patients staying on GLP-1s longer, or is the discontinuation rate still the same, given physicians' increased experience?

Meta-analyses still suggest a median duration of 6-9 months on GLP-1 therapy, with no significant change observed. Oral GLP-1s are seeing lower doses and less titration. The "million discontinuers a month" remains a key figure, indicating a huge opportunity for Revita as these patients face rapid weight regain.

“The data that I'm seeing is that patients are, all the meta-analyses I'm seeing are now suggesting that the median duration of time on therapy is still in the six to nine month range.”

asked by Angela Qian · answered by Harith Rajagopalan

Early thoughts on Revita pricing and what kind of preliminary data to expect for Rejuva later this year.

Revita pricing details will be presented at the Investor Day, focusing on the health economic value proposition. For Rejuva, the primary expectation for preliminary data is the safety and tolerability of Rejuva-001 and the feasibility/safety of its device delivery in the first sentinel patient over 14 days.

“With respect to Rejuva, I would point you to our earlier statement that like the first most important thing for us to communicate is the safety and tolerability of Rejuva 001 through that first 14-day sentinel period and the safety and feasibility of the Rubita device delivery.”

asked by Unknown Speaker · answered by Harith Rajagopalan